Parse Biosciences, Wellcome Sanger Institute, and Helmholtz Munich Collaborate to Pioneer Cancer Plasticity Atlas for Therapy Response Prediction

Leveraging Parse’s cutting-edge GigaLab facility and Evercode chemistry, this partnership will generate massive, high-quality single cell RNA sequencing datasets at unprecedented speed, enabling AI-driven cancer research and drug discovery to better predict therapeutic resistance and guide future treatments.